Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An update from Lisata Therapeutics ( (LSTA) ) is now available.
On November 6, 2025, Lisata Therapeutics reported its third-quarter financial results, highlighting positive data from clinical studies involving certepetide, a promising investigational drug for solid tumors. The company announced strategic alliances and a global license agreement, extending its cash runway into early 2027, and anticipates further data releases to bolster its market position.
The most recent analyst rating on (LSTA) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Lisata Therapeutics stock, see the LSTA Stock Forecast page.
Spark’s Take on LSTA Stock
According to Spark, TipRanks’ AI Analyst, LSTA is a Neutral.
Lisata Therapeutics is navigating through financial difficulties with persistent losses and negative cash flows. The stock’s technical indicators and valuation reflect a challenging financial position. However, recent advancements in clinical trials and regulatory achievements offer potential upside, albeit with high risk.
To see Spark’s full report on LSTA stock, click here.
More about Lisata Therapeutics
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing innovative therapies for advanced solid tumors and other serious diseases.
Average Trading Volume: 65,776
Technical Sentiment Signal: Strong Sell
Current Market Cap: $21.63M
Find detailed analytics on LSTA stock on TipRanks’ Stock Analysis page.